All In Biotech

Drug Trial Radar · NCT03281538

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Last checked: Nov 19, 2026Latest source record: Oct 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

288

Actual

Start

Aug 14, 2017

Primary completion

Feb 11, 2020

Study completion Feb 11, 2020

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.

Conditions

  • Uremic Pruritus

Interventions

  • CR845Drug

    IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With AEsTime frame: Up to 52 weeks

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Chula Vista, California

  • Cara Therapeutics Study Site

    El Centro, California

  • Cara Therapeutics Study Site

    Long Beach, California

  • Cara Therapeutics Study Site

    Northridge, California

  • Cara Therapeutics Study Site

    Denver, Colorado

  • Cara Therapeutics Study Site

    Hollywood, Florida

  • Cara Therapeutics Study Site

    Tampa, Florida

  • Cara Therapeutics Study Site

    Winter Park, Florida

  • Cara Therapeutics Study Site

    Albany, Georgia

  • Cara Therapeutics Study Site

    Augusta, Georgia

  • Cara Therapeutics Study Site

    Meridian, Idaho

  • Cara Therapeutics Study Site

    Springfield, Massachusetts

  • Cara Therapeutics Study Site

    Roseville, Michigan

  • Cara Therapeutics Study Site

    Kansas City, Missouri

  • Cara Therapeutics Study Site

    Albuquerque, New Mexico

  • Cara Therapeutics Study Site

    Gallup, New Mexico

  • Cara Therapeutics Study Site

    Mineola, New York

  • Cara Therapeutics Study Site

    Ridgewood, New York

  • Cara Therapeutics Study Site

    Bethlehem, Pennsylvania

  • Cara Therapeutics Study Site

    Knoxville, Tennessee

  • Cara Therapeutics Study Site

    El Paso, Texas

  • Cara Therapeutics Study Site

    San Antonio, Texas

  • Cara Therapeutics Study Site

    San Antonio, Texas

  • Cara Therapeutics Study Site

    San Antonio, Texas

  • Cara Therapeutics Study Site

    St. George, Utah

  • Cara Therapeutics Study Site

    Wauwatosa, Wisconsin

  • Cara Therapeutics Study Site

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.